About AvimerBio
A Breakthrough Protein Therapeutics Company Focused on Treatment of Inflammatory and Oncological Diseases
50M+ Americans suffer from chronic immune and inflammatory diseases, and current drug treatments are failing them.
Current drugs act by blocking cellular targets to treat infections or lower cancer risks, but they are often not curative
Larger fully human particles replicate the avidity and geometry of cell-cell signaling
Drugs that activate key sentinel immune cells have the potential to provide lasting relief
Therapeutic Applications
Proteins designed with specific valency and orientation can be optimized to present functional payloads
Targeted Drug Delivery
Protein nanoparticles act as carriers, delivering substances to cells with specificity to enhance bioactivity and minimize off-target effects
SM Discovery & Protein Imaging
Protein nanoparticles provide unique scaffolds to enable cryo-EM visualization of SM drug binding
The Problem
Millions of patients have no good treatment options
~30%
of RA & IBD patients fail existing biologics
17M+
patients with severe autoimmune disease in US & Europe
$40B+
addressable market still under-served by current drugs
Existing biologics suppress, rather than restore. TNF/JAK inhibitors control symptoms but don't address the root cause — immune imbalance.
Single-target approaches hit walls. Complex autoimmune diseases involve multiple pathways; blocking one lets others compensate.
Agonist antibodies have failed to cluster receptors. Standard mAbs are bivalent and geometrically limited — they can't recreate the clustering needed for true immune reset.
The Solution: Avibodies
Programmable protein nanoparticles that do what antibodies can't
Programmable Geometry
Receptor clustering tuned by design
Architecture, avidity and dosing control agonism
Fully Human
Antibody-like safety & developability
Standard CHO production, Tm 75°C, >200 mg/L titers
High Avidity, Low Off-Target
Binds high-expressing pathogenic cells selectively
Avid display of targeted payloads with ideal geometry for potent activity
AI-Optimized
Rapid optimization of NanoParticles using AI
Superior thermal stability, rigidity, and manufacturability of scaffolds
Novel Protein Therapeutic NanoParticles
Proprietary technology allows the design of fully human nanoparticles with targeted presentation geometries and sequence composition to deliver potent therapeutics
Enables Rational Drug Design for Challenging Targets
Most cellular proteins are too small to study by cryo EM (<50kD)
New strategy developed to use protein nanoparticles as large and symmetric scaffolds
Modular design allows for rigid binding of small to medium protein cargos and potentially GPCRs
Structure determination reveals cargo structure and drug complexes
Successful imaging at < 3 Å for SM discovery
We are partnering with pharma and biotech companies to enable structure determination and small molecule therapeutic design
Traction & IP
Drug candidates in hand. IP filed. Ready for POC studies.
Lead Avibodies Synthesized
Multiple therapeutically relevant cytokine payloads across RA, UC, SLE — made with standard CHO manufacturing. High expression titers (>200 mg/L), thermal stability (Tm 75°C), homogeneous purification — production-ready profiles.
Intellectual Property
3 patents filed — biologics, CryoEM scaffolds & immunogens. Biologics 2025 (US Patent 63/757,279), CryoEM Scaffolds 2026 (US Provisional 63/957,287), Immunogens 2026 (US Provisional 63/959,782)
Non-Dilutive Revenue
Ongoing Pfizer partnership + 2nd & 3rd pharma projects generating non-dilutive funding and validating platform.
Leadership
World-class team with 100+ years of biologics experience
Todd Yeates, PhD
CSOInventor of designed protein cages, 250+ publications in protein design & AI, UCLA Professor 25+ years
Peter Bowers, PhD
CEOLed 12 biologics to clinic, 2 FDA-approved antibodies, SVP at TRexBio & AnaptysBio
Adam Sragovicz
CFOLed IPOs & M&A transactions, Ex-Conduit Pharma, KPMG, 20-year capital markets track record
Jeff Southerton, PhD MBA
Head, BD30 yrs pharma BD, Ex-Pfizer. Consultant to UroGen Pharma and Mabwell Tx. Biopharma strategy & pipeline growth
Robin Aglietti, PhD
Head, Protein Sciences15 years deep protein engineering expertise and biologics development, Ex-Genentech, Trex Bio, Surrozen
Pat Gearing, PhD
Head, CMC30 years biologics development, Led Tepezza, Bexxar, Adcetris to market, Ex-Pfizer partnerships lead
Get In Touch
Contact us to explore our protein therapeutics, discuss collaboration opportunities, or learn about our custom protein-design services